Renal cell carcinoma - historical
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main RCC page for current regimens.
9 regimens on this page
9 variants on this page
|
Metastatic disease, first-line
Medroxyprogesterone acetate monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Medical Research Council Renal Cancer Collaborators 1999 (MRC RE01) | Phase III (C) | IFN alfa-2a | Seems to have inferior OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Hormonotherapy
References
- Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999 Jan 2;353(9146):14-7. link to original article contans protocol PubMed
Metastatic disease, second-line
FC, then allo HSCT
back to top |
FC: Fludarabine & Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Childs et al. 2000 | Non-randomized, <20 pts |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days -5 to -1
- Cyclophosphamide (Cytoxan) 60 mg/kg IV once per day on days -7 & -6
Immunotherapy
- Allogeneic stem cells transfused on day 0
One course
References
- Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. link to original article contains verified protocol PubMed
Megestrol acetate monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Ravaud et al. 2008 | Phase III (C) | Lapatinib | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. Kelley & Baker 1961 examined a variety of progestins and is included for historic interest.
Hormonotherapy
References
- Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol. 2008 May 10;26(14):2285-91. link to original article PubMed